<DOC>
	<DOCNO>NCT01940497</DOCNO>
	<brief_summary>This non-randomized , multicenter , open-label study ass safety efficacy subcutaneously administer trastuzumab participant early locally advanced HER2-positive breast cancer two sequential cohort . First 120 participant treat subcutaneous ( SC ) trastuzumab ( 600 milligram per 5 milliliter [ mg/5mL ] vial ( Cohort A ) subsequent 120 participant treat SC trastuzumab prefilled single use injection device ( SID ) ( Cohort B ) . Participants cohort receive neo-adjuvant adjuvant chemotherapy consist 4 cycle anthracyclines follow 4 cycle paclitaxel weekly docetaxel every 3 week ( q3w ) combination SC trastuzumab ( 600 milligram [ mg ] ) q3w 14 cycle SC trastuzumab ( 600 mg ) q3w alone .</brief_summary>
	<brief_title>SCHEARLY Study : A Study Safety Subcutaneously Administered Trastuzumab ( Herceptin ) Participants With Early Locally Advanced Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm nonmetastatic primary invasive adenocarcinoma breast . Stage disease : T14 ( T describe size tumour 1 4 ) , N03 ( N describe nearby lymph node ) , M0 ( M describe distant metastasis ) HER2positive disease immunohistochemistry ( IHC ) 3+ situ hybridization ( ISH ) positive Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Left ventricular ejection fraction ( LVEF ) great equal ( &gt; /= ) 55 percent ( % ) measure echocardiography ( ECHO ) multiple gated acquisition ( MUGA ) scan prior first dose trastuzumab SC Intact skin site SC injection thigh History malignancy , except participant curatively treat carcinoma situ cervix basal cell carcinoma participant curatively treated malignancy , breast cancer , diseasefree least 5 year Severe dyspnea rest require supplementary oxygen therapy Concurrent serious disease may interfere plan treatment , include severe pulmonary conditions/illness Serious cardiac illness medical condition would preclude use trastuzumab , specifically : history document congestive heart failure ( CHF ) , highrisk uncontrolled arrhythmia , angina pectoris require medication , clinically significant valvular disease , evidence transmural infarction electrocardiogram ( ECG ) , diagnose poorly control hypertension Known infection human immunodeficiency virus ( HIV ) , active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) Pregnant lactate woman Concurrent enrolment another clinical trial use investigational anticancer treatment , include hormonal therapy , bisphosphonate therapy immunotherapy , within 28 day prior first dose study treatment Known hypersensitivity trastuzumab , murine protein , excipients Herceptin include hyaluronidase , adhesive SC device ( cohort B ) , history severe allergic immunological reaction , e.g . difficulty control asthma Inadequate bone marrow , hepatic renal function Hormonal treatment concomitant chemotherapy ( allow adjuvant phase adjuvant trastuzumab SC ) Preexisting motor sensory neuropathy Grade great ( &gt; ) 1 Sincronous bilateral invasive breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>